<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR941003-0-00065</title>
	</head>
	<body>
		<main>
			<p><!-- PJG STAG 4700 -->  <!-- PJG ITAG l=11 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Description of Respondents:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Businesses.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <TABLE>  <!-- PJG tableformat 6,L2,i1,s50,12,12,12,12,12 -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=95 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=1 f=4 --> Estimated Annual Reporting and Recordkeeping Burden <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 007 0150 intable --> 1Section <!-- PJG 0012 frnewline -->  <!-- PJG 007 0150 intable --> 1No. of respondents <!-- PJG 0012 frnewline -->  <!-- PJG 007 0150 intable --> 1No. of responses per respondent <!-- PJG 0012 frnewline -->  <!-- PJG 007 0150 intable --> 1Total annual responses  <!-- PJG 0012 frnewline -->  <!-- PJG 007 0150 intable --> 1Hours per  <!-- PJG 0012 frnewline -->  <!-- PJG 007 0120 intable --> response <!-- PJG 0012 frnewline -->  <!-- PJG 007 0150 intable --> 1Total hours <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 007 0152 intable -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=01 g=1 f=4 --> 314.50(i)  <!-- PJG 007 0104 intable --> 8  <!-- PJG 007 0104 intable --> 1  <!-- PJG 007 0104 intable --> 8 <!-- PJG 007 0104 intable --> 2  <!-- PJG 007 0104 intable --> 16 <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 314.50(j)  <!-- PJG 007 0104 intable --> 50  <!-- PJG 007 0104 intable --> 1  <!-- PJG 007 0104 intable --> 50  <!-- PJG 007 0104 intable --> 2  <!-- PJG 007 0104 intable --> 100 <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 314.52  <!-- PJG 007 0104 intable --> 30  <!-- PJG 007 0104 intable --> 1  <!-- PJG 007 0104 intable --> 30  <!-- PJG 007 0104 intable --> 8  <!-- PJG 007 0104 intable --> 240 <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 314.53  <!-- PJG 007 0104 intable --> 200  <!-- PJG 007 0104 intable --> 1  <!-- PJG 007 0104 intable --> 200  <!-- PJG 007 0104 intable --> 1  <!-- PJG 007 0104 intable --> 200 <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 314.94(a)(12)  <!-- PJG 007 0104 intable --> 215  <!-- PJG 007 0104 intable --> 1  <!-- PJG 007 0104 intable --> 215  <!-- PJG 007 0104 intable --> 2  <!-- PJG 007 0104 intable --> 430 <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 314.95  <!-- PJG 007 0104 intable --> 30  <!-- PJG 007 0104 intable --> 1  <!-- PJG 007 0104 intable --> 30  <!-- PJG 007 0104 intable --> 16  <!-- PJG 007 0104 intable --> 480 <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 314.107  <!-- PJG 007 0104 intable --> 10  <!-- PJG 007 0104 intable --> 1  <!-- PJG 007 0104 intable --> 10  <!-- PJG 007 0104 intable --> 10  <!-- PJG 007 0104 intable --> 10 <!-- PJG 007 0162 intable --> n,n,n,n,n,s <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=03 g=1 f=4 --> Total  <!-- PJG 007 0104 intable -->   <!-- PJG 007 0104 intable -->   <!-- PJG 007 0104 intable -->   <!-- PJG 007 0104 intable -->   <!-- PJG 007 0104 intable --> 1,476  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  </TABLE>  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=11 g=1 f=4 --> There were no comments received on the Paperwork Reduction Act clearance submission or on the burden estimates. The agency has, however, revised the estimate for ANDA's under &sect;314.94 based on its latest figures for the number of ANDA's received.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=84 g=1 f=4 --> VII. References  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=4 --> The following references have been placed on display in the Dockets Management Branch (HFA&hyph;305), Food and Drug Administration, rm. 1&hyph;23, 12420 Parklawn Dr., Rockville, MD 20857, and may be seen by interested persons between 9 a.m. and 4 p.m., Monday through Friday.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=21 g=1 f=4 --> 1. Letter dated September 28, 1992, from Jane E. Henney, Deputy Commissioner for Operations, to Alan H. Kaplan and Richard S. Morey, Kleinfeld, Kaplan and Becker (FDA Docket No. 90P&hyph;0455).  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 2. Letter dated December 8, 1987, from John M. Taylor, Associate Commissioner for Regulatory Affairs, to Bruce J. Brennan, Senior Vice President and General Counsel (FDA Docket No. 86P&hyph;0235/CP).  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=84 g=1 f=4 --> List of Subjects in 21 CFR Part 314  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=4 --> Administrative practice and procedure, Confidential business information, Drugs, Reporting and recordkeeping requirements.  <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=11 g=1 f=4 --> Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs, 21 CFR part 314 is amended as follows:  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=52 g=1 f=4 --> PART 314_APPLICATIONS FOR FDA APPROVAL TO MARKET A NEW DRUG OR AN ANTIBIOTIC DRUG  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=4 --> 1. The authority citation for 21 CFR part 314 continues to read as follows:  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=21 g=1 f=4 --> Authority:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=1 --> Secs. 201, 301, 501, 502, 503, 505, 506, 507, 701, 704, 721 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 321, 331, 351, 352, 353, 355, 356, 357, 371, 374, 379e).  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=11 g=1 f=1 --> 2. Section 314.50 is amended by redesignating existing paragraph (h) as paragraph (k) and by adding new paragraphs (h), (i), and (j) to read as follows:  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=80 g=1 f=1 --> &sect;314.50  <!-- PJG /ITAG -->  <!-- PJG ITAG l=89 g=1 f=1 --> Content and format of an application.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=37 g=1 f=1 --> * * * * *  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (h)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Patent information.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> The application is required to contain the patent information described under &sect;314.53.  <!-- PJG 0012 frnewline --> (i)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Patent certification <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> _(1)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Contents.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> A 505(b)(2) application is required to contain the following:  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> (i)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Patents claiming drug, drug product, or method of use.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (A) Except as provided in paragraph (i)(2) of this section, a certification with respect to each patent issued by the United States Patent and Trademark Office that, in the opinion of the applicant and to the best of its knowledge, claims a drug (the drug product or drug substance that is a component of the drug product) on which investigations that are relied upon by the applicant for approval of its application were conducted or that claims an approved use for such drug and for which information is required to be filed under section 505 (b) and (c) of the act and &sect;314.53. For each such patent, the applicant shall provide the patent number and certify, in its opinion and to the best of its knowledge, one of the following circumstances:  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> ( <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> 1 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> ) That the patent information has not been submitted to FDA. The applicant shall entitle such a certification ``Paragraph I Certification'';  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> ( <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> 2 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> ) That the patent has expired. The applicant shall entitle such a certification ``Paragraph II Certification'';  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> ( <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> 3 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> ) The date on which the patent will expire. The applicant shall entitle such a certification ``Paragraph III Certification''; or  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> ( <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> 4 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> ) That the patent is invalid, unenforceable, or will not be infringed by the manufacture, use, or sale of the drug product for which the application is submitted. The applicant shall entitle such a certification ``Paragraph IV Certification''. This certification shall be submitted in the following form:  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=20 g=1 f=1 --> I, ( <!-- PJG /ITAG -->  <!-- PJG ITAG l=20 g=1 f=3 --> name of applicant <!-- PJG /ITAG -->  <!-- PJG ITAG l=20 g=1 f=1 --> ), certify that Patent No.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=20 g=7 f=2 --> XXXXXX <!-- PJG /ITAG -->  <!-- PJG ITAG l=20 g=1 f=1 -->  ( <!-- PJG /ITAG -->  <!-- PJG ITAG l=20 g=1 f=3 --> is invalid, unenforceable, or will not be infringed by the manufacture, use, or sale of <!-- PJG /ITAG -->  <!-- PJG ITAG l=20 g=1 f=1 --> ) ( <!-- PJG /ITAG -->  <!-- PJG ITAG l=20 g=1 f=3 --> name of proposed drug product <!-- PJG /ITAG -->  <!-- PJG ITAG l=20 g=1 f=1 --> ) for which this application is submitted.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=10 g=1 f=1 --> The certification shall be accompanied by a statement that the applicant will comply with the requirements under &sect;314.52(a) with respect to providing a notice to each owner of the patent or their representatives and to the holder of the approved application for the drug product which is claimed by the patent or a use of which is claimed by the patent and with the requirements under &sect;314.52(c) with respect to the content of the notice.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (B) If the drug on which investigations that are relied upon by the applicant were conducted is itself a licensed generic drug of a patented drug first approved under section 505(b) of the act, the appropriate patent certification under this section with respect to each patent that claims the first-approved patented drug or that claims an approved use for such a drug.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> (ii)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> No relevant patents.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> If, in the opinion of the applicant and to the best of its knowledge, there are no patents described in paragraph (i)(1)(i) of this section, a certification in the following form:  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=20 g=1 f=1 --> In the opinion and to the best knowledge of ( <!-- PJG /ITAG -->  <!-- PJG ITAG l=20 g=1 f=3 --> name of applicant <!-- PJG /ITAG -->  <!-- PJG ITAG l=20 g=1 f=1 --> ), there are no patents that claim the drug or drugs on which investigations that are relied upon in this application were conducted or that claim a use of such drug or drugs.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG /STAG --></p>
		</main>
</body></html>
            